It’s only a small-scale project, but it’s exciting to see new funding models being tried out for drug development.
Here on Techdirt we’ve been pretty scathing about the way that Big Pharma develops drugs — often poorly — and then uses patent monopolies to keep prices so high that only rich Westerners can afford them. Of course, it’s easy to complain about the flaws of the current approach, but are there any alternatives? We’ve already covered one — using prizes – and now Carl Levinson points us to another potentially powerful approach: crowdsourcing. It’s already been adopted by ‘Project Marilyn’ to develop a patent-free anti-cancer drug:
The campaign will fund a xenograft experiment, which is the next step in developing the promising anti-cancer compound “9DS”. This experiment needs to be completed before 9DS can move on to clinical trials.
Here are some more details of both the drug and the project:
The drug candidate 9DS was developed at the University of Maryland. The last work done on the drug showed that it had activity against cancer competitive with leading cancer drugs such as taxol. Moreover, 9DS is also likely to have lower side effects than most chemotherapies, since a related compound, SJG-136, seems to have low side effects in early clinical trials.
Project Marilyn involves: production of more 9DS, and submitting 9DS to a xenograft study (‘curing cancer in mice’). This is the next step in drug development and an important one on the way to doing clinical (human) studies. The process we’re seeking to fund should take approximately 6 months. If we receive more funding, we will add stretch goals, such as further preclinical experiments on 9DS, development 9DS analogs, or other exciting anti-cancer ideas.
Of course, even if enough money is raised — at the time of writing, just over a quarter of the crowdfunding target has been pledged — there’s still much more work to be done before the drug can be sold to the public. An article in the Times of San Diego explains what will happen next:
The Latest on: Patent-free drug
[google_news title=”” keyword=”Patent-free drug” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Patent-free drug
- This World IP Day, Governments Must Embrace Patent Protectionon April 25, 2024 at 10:00 pm
Day, an occasion to champion the protections that have resulted in countless life-saving treatments for patients. Unfortunately, not everyone appreciates t ...
- Copycats take bite out of AbbVie’s best-selling Humira drugon April 25, 2024 at 6:22 am
When AbbVie’s record-breaking immunology drug Humira came off-patent early last year after generating more than $200bn in sales for the drugmaker over two decades, a number of cheaper copycat products ...
- Wellness With Age: Navigating the high cost of prescription drugson April 24, 2024 at 1:30 am
According to a recent article in The New York Times, citizens in the United States pay more for prescription drugs than any other country in the world!
- US Supreme Court rejects Vanda's bid to revive patents on sleep disorder drug Hetliozon April 22, 2024 at 12:49 pm
The High Court has rebuffed Vanda’s bid to contest the May 2023 ruling from the U.S. Court of Appeals for the Federal Circuit roughly four months after the company appealed to the Supreme Court to ...
- EXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patenton April 22, 2024 at 5:00 am
Adial Pharmaceuticals' genetic diagnostic patent, expanding treatment for alcohol and drug dependencies. CEO highlights the significance.
- Top 10 Drug Delivery Technologies Market Size and Scope, Industry snapshot, Leading Companies and Opportunity Analysis by 2032on April 18, 2024 at 1:56 pm
Growing need for effective delivery of novel biopharmaceuticals and pharmaceutical coupled with innovation in drug delivery technologies are key driving forces of market. Apart from this, patent ...
- Orexo receives US patent for its nasal epinephrine powder product OX640on April 18, 2024 at 4:29 am
Orexo receives US patent for its nasal epinephrine powder product OX640: Uppsala, Sweden Thursday, April 18, 2024, 17:00 Hrs [IST] Orexo AB, a Swedish pharmaceutical company with ...
- Defending the Bayh-Dole Act, or why governments shouldn’t dictate the cost of drugson April 13, 2024 at 1:00 pm
Innovators in the U.S. must maintain their intellectual property rights if they are to provide the returns expected by current and future investors.
via Bing News